Quantcast

New Finding in ALS Strengthens Role of RNA in Disease

June 25, 2013

Researchers have shown that an ALS-related protein is involved in clearing RNA-containing material that builds up in cells, including neurons. The finding suggests that loss of that clearance ability may contribute to the disease.

Washington, DC (PRWEB) June 25, 2013

In work funded by The ALS Association through its support of Regina-Maria Kolaitis, Ph.D., a Milton Safenowitz Post-Doctoral Fellow, researchers have shown that an ALS-related protein is involved in clearing RNA-containing material that builds up in cells, including neurons. The finding suggests that loss of that clearance ability may contribute to the disease. The study was published in the journal Cell. To read the abstract, visit http://www.cell.com/abstract/S0092-8674%2813%2900643-0.

ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that affects neurons (nerve cells) in the brain and the spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within two to five years of diagnosis. There is no cure and no life-prolonging treatments for the disease.

The material affected is a combination of protein and RNA called stress granules. RNA is used by cells to make proteins. Stress granules form temporarily when cells are under stress. The researchers found that mutations in a gene for valosin-containing protein (VCP) reduced the ability of cells to move the stress granules to vacuoles, cell structures that degrade and recycle many parts of the cell. Mutation in VCP is one cause of ALS.

“This study contributes to the growing understanding of the role of RNA processing in ALS,” said Lucie Bruijn, Ph.D., Chief Scientist for The Association. “The results strengthen the case that inability to handle RNA during stress may be a significant factor in the disease.”

The research was performed by Ross Buchan, Ph.D., and Regina-Maria Kolaitis, Ph.D., under the direction of J. Paul Taylor, M.D., Ph.D., and Roy Parker, Ph.D. Drs. Buchan and Parker are from the University of Colorado at Boulder, and Drs. Kolaitis and Taylor are at Saint Jude Children’s Research Hospital in Memphis, Tennessee. Dr. Kolaitis received The Milton-Safenowitz Post-Doctoral Fellowship from The ALS Association in 2012.

The Milton Safenowitz Post-Doctoral Fellowship for ALS Research Award encourages and facilitates promising young scientists to enter the ALS field. Funding for this two-year research award is made possible by the generosity of the Safenowitz family through the Greater New York Chapter of The ALS Association and is in memory of Mr. Safenowitz, who died of ALS in 1998.

About The ALS Association

The ALS Association is the only national non-profit organization fighting Lou Gehrig’s Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure. For more information about The ALS Association, visit our website at http://www.alsa.org.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/6/prweb10867170.htm


Source: prweb



comments powered by Disqus